Anti-Human RAIDD (CT)
Code | Size | Price |
---|
LEI-R1002-20ug | 20 ug | £199.00 |
Quantity:
LEI-R1002-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Images
Further Information
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
PN:R1004
Long Description:
Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain (DD)-containing receptors, TNFR1 and Fas. The death signals are transduced by a group of DD-containing adapter molecules. A novel cell death adapter was recently identified by two independent groups and designated RAIDD (RIP-associated ICH-1/CED-3-homologous protein with DD) and CRADD (caspase and RIP adapter with DD),1 RAIDD contains a DD and a CARD (for caspase recruitment domain) which interact with RIP and caspase, respectively, to transduce death signals. RAIDD is constitutively expressed in many tissues and mediates apoptosis caused by Fas and TNFR-1.
Target:
RAIDD
References
1. Duan, H. et al. (1997) Nature 385:86 2. Ahmad, M. et al. (1997) Cancer Res. 57:615 3. Hofmann, K. et al. (1997) Trends Biochem. Sci. 22:155
Related Products
Product Name | Product Code | Supplier | Anti-Human RAIDD (Intermediate Domain) | LEI-R1003 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RAIDD (CT) Blocking Peptide | LEI-R1004 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RAIDD (Intermediate Domain) Blocking Peptide | LEI-R1005 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||